Base Editing & Prime Editing Patents

Base editing and prime editing patents cover base-editor architecture innovations; prime-editor architecture innovations; deaminase, guide-RNA, and delivery innovations; and the foundational precision-editing platforms — with IP held by editing-platform companies and the academic inventor's institution. MAJOR BASE/PRIME-EDITING PATENT HOLDERS: BEAM THERAPEUTICS: the base-editing leader (founded by David Liu, Feng Zhang, and J. Keith Joung), licensing the foundational base-editing IP from the Broad Institute — adenine and cytosine base editors, BEAM-101 (ex vivo base-edited cells for sickle cell disease), and in vivo LNP-delivered programs. PRIME MEDICINE: the prime-editing company (also David Liu-founded), licensing prime editing from the Broad — 'search-and-replace' editing using a prime editing guide RNA and reverse transcriptase. VERVE THERAPEUTICS (Eli Lilly): in vivo base editing of cardiovascular targets (PCSK9, ANGPTL3) delivered by LNP. THE BROAD INSTITUTE / DAVID LIU: the foundational academic patents on base editing (2016) and prime editing (2019) — the core IP that Beam and Prime Medicine license. OTHERS: Intellia, Pairwise (agriculture base editing), Metagenomi, and CRISPR-platform holders whose Cas proteins underlie these editors. Base-editor and prime-editor architectures (and the deaminases/reverse transcriptases that power them) are the core patent domains — built atop, and dependent on, the underlying CRISPR-Cas IP.

Cytosine-base-editor innovations; adenine-base-editor innovations; deaminase-engineering innovations; and editing-window and specificity innovations represent core base-editing patent domains — and base editors make precise single-letter DNA changes WITHOUT cutting both DNA strands. CYTOSINE-BASE-EDITOR (CBE) PATENTS: a cytidine deaminase (APOBEC/AID family) fused to a catalytically-impaired Cas9 (nickase or dead Cas9) plus uracil-glycosylase inhibitor UGI, converting C·G base pairs to T·A — including deaminase variants and architecture. ADENINE-BASE-EDITOR (ABE) PATENTS: an engineered (laboratory-evolved) deoxyadenosine deaminase (TadA, originally a tRNA enzyme evolved to act on DNA) fused to Cas9 nickase, converting A·T to G·C — the evolved TadA variants are a key, valuable invention. DEAMINASE-ENGINEERING PATENTS: narrowing the editing window (precision), reducing off-target DNA and RNA editing (deaminase mutants with lower promiscuity), and expanding the editable sequence context (different PAMs via different Cas variants). SPECIFICITY / FIDELITY PATENTS: high-fidelity editors, reduced bystander editing, and context optimization. Base editing's appeal — making point mutations without double-strand breaks (avoiding indels/translocations) — makes the specific editor architectures and engineered deaminases (especially the evolved TadA for adenine editing) the highest-value base-editing IP.

Prime-editor architecture innovations; prime-editing guide-RNA (pegRNA) innovations; editing-efficiency and scope innovations; and delivery innovations represent additional precision-editing patent domains — and prime editing can install any of the 12 point mutations plus small insertions/deletions without double-strand breaks or donor DNA. PRIME-EDITOR PATENTS: the prime editor — a Cas9 nickase fused to an engineered reverse transcriptase that, guided by a prime editing guide RNA, nicks one strand and writes a new sequence templated by the pegRNA ('search and replace'); including reverse-transcriptase variants and editor architecture (PE2/PE3/PEmax and dual-pegRNA twin/PASTE approaches). pegRNA PATENTS: the prime editing guide RNA design — the primer-binding site and reverse-transcriptase template that encode the desired edit, plus pegRNA stabilization (structured motifs preventing degradation), nicking-guide design, and the MMR-evasion strategies that boost efficiency. SCOPE / EFFICIENCY PATENTS: large-insertion prime editing (integrating whole genes via recombinase landing sites — twinPE/PASTE), efficiency-enhancing helper proteins, and multiplexing. DELIVERY PATENTS: lipid-nanoparticle LNP delivery (transient, for in vivo liver — Verve/Beam), AAV (split-editor due to size), virus-like particles, and ex vivo electroporation; size is a delivery challenge because these editors are large. Prime-editor and pegRNA design, plus large-insertion/delivery solutions, are the highest-value prime-editing IP.

Base/prime editing startup IP strategy must navigate the Broad Institute/David Liu foundational base-editing and prime-editing patents (exclusively/semi-exclusively licensed to Beam and Prime Medicine — a startup likely needs a license), the underlying CRISPR-Cas9 patent estate and the Broad-vs-Berkeley interference dispute (your editor uses a Cas protein someone else may control), Beam/Verve in vivo and target patents, and a §101-light landscape (these are concrete molecular machines and compositions, not abstract ideas); understand that the core platforms are foundationally patented (FTO/licensing is the central issue), that the durable startup IP is in novel editor architectures, engineered deaminases/reverse transcriptases, pegRNA/guide designs, delivery, and specific therapeutic targets, and that delivery (size) and specificity are the technical battlegrounds; identify whitespace in improved editors, novel deaminases, large-insertion editing, delivery, and new targets. BASE/PRIME-EDITING STARTUP IP STRATEGY: THE PLATFORMS ARE FOUNDATIONALLY PATENTED — LICENSING IS THE CENTRAL ISSUE: base editing and prime editing are Broad/Liu inventions licensed to Beam and Prime Medicine, AND they depend on underlying CRISPR-Cas IP (Broad vs Berkeley) — map and secure freedom-to-operate/licenses before building; NOVEL EDITORS, DEAMINASES, AND REVERSE TRANSCRIPTASES ARE THE STARTUP IP: engineer a new deaminase, a smaller/more-precise editor, a better reverse transcriptase, or a novel pegRNA design to create defensible, possibly design-around IP; DELIVERY (SIZE) IS A HIGHEST-VALUE TECHNICAL PROBLEM: base/prime editors are large — LNP, split-AAV, VLP, and compact-Cas solutions that enable in vivo delivery are valuable, patentable whitespace; LARGE-INSERTION EDITING (twinPE/PASTE) IS AN OPEN FRONTIER: writing whole genes precisely (beyond point mutations) is a fast-moving, high-value area; SPECIFICITY (OFF-TARGET DNA/RNA) IS A DIFFERENTIATOR: higher-fidelity editors reducing bystander/off-target editing are patentable and clinically decisive; THERAPEUTIC TARGETS ARE COMPOSITION/METHOD IP: a specific edit at a specific target (with the editor + guide) is protectable; WHEN TO PATENT: NOVEL EDITOR/EDIT WITH MEASURED PERFORMANCE: file once a tool shows measured results (editing efficiency % + product purity/precision + off-target rate + delivery/in vivo efficacy) vs. existing base/prime editors — measured editing efficiency, precision/purity, off-target rate, and delivery/in vivo performance are the critical precision-editing IP metrics; KEY FTO CHECKLIST: Broad/David Liu base editing (CBE APOBEC + Cas9 nickase + UGI; ABE evolved TadA) and prime editing (Cas9 nickase + RT + pegRNA) foundational; Beam/Prime Medicine/Verve licenses; underlying CRISPR-Cas9 (Broad vs Berkeley) FTO; PE2/PE3/PEmax, twinPE/PASTE large insertion; pegRNA primer-binding-site/RT-template/stabilization, MMR evasion; engineered deaminase/RT variants high-fidelity; LNP/split-AAV/VLP delivery; off-target DNA/RNA editing; composition-of-matter editor + target edit.